Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

cyclin-dependent kinase inhibitor PF-06873600

An orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with potential antineoplastic activity. Upon administration, PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CDK inhibitor PF-06873600
Code name:PF 06873600
PF-06873600
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search